These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 7922255)

  • 1. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
    Parving HH; Rossing P
    Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is antihypertensive treatment the same for NIDDM and IDDM patients?
    Parving HH
    Diabetes Res Clin Pract; 1998 Apr; 39 Suppl():S43-7. PubMed ID: 9649959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolving strategies for renoprotection: diabetic nephropathy.
    Parving HH; Hovind P; Rossing K; Andersen S
    Curr Opin Nephrol Hypertens; 2001 Jul; 10(4):515-22. PubMed ID: 11458033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of blood pressure and antihypertensive treatment on incipient and overt nephropathy, retinopathy, and endothelial permeability in diabetes mellitus.
    Parving HH
    Diabetes Care; 1991 Mar; 14(3):260-9. PubMed ID: 2044441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and slowing down the progression of the diabetic nephropathy through antihypertensive therapy.
    Bretzel RG
    J Diabetes Complications; 1997; 11(2):112-22. PubMed ID: 9101397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does antihypertensive treatment prevent progression of microalbuminuria to overt proteinuria in insulin-dependent diabetic patients?
    Passa P
    J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S91-6. PubMed ID: 1457766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The management of diabetic proteinuria. Which antihypertensive agent?
    Cooper ME; Doyle AE
    Drugs Aging; 1992; 2(4):301-9. PubMed ID: 1504444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus.
    McKenna K; Thompson C
    Scott Med J; 1997 Aug; 42(4):99-104. PubMed ID: 9507584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.
    Goa KL; Haria M; Wilde MI
    Drugs; 1997 Jun; 53(6):1081-105. PubMed ID: 9179532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
    Laffel LM; McGill JB; Gans DJ
    Am J Med; 1995 Nov; 99(5):497-504. PubMed ID: 7485207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of microalbuminuria as an indicator of incipient diabetic nephropathy: therapeutic implications.
    Chiarelli F; Verrotti A; Mohn A; Morgese G
    Ann Med; 1997 Oct; 29(5):439-45. PubMed ID: 9453292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy.
    Parving HH; Hovind P
    Curr Hypertens Rep; 2002 Oct; 4(5):387-93. PubMed ID: 12217258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renoprotective action of angiotensin-converting enzyme inhibition in diabetes mellitus.
    Parving HH
    J Cardiovasc Pharmacol; 1992; 19 Suppl 6():S19-24. PubMed ID: 1382160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Micro-albuminuria and the organ-damage concept in antihypertensive therapy for patients with insulin-dependent diabetes mellitus.
    Mogensen CE; Petersen MM; Hansen KW; Christensen CK
    J Hypertens Suppl; 1992 Apr; 10(1):S43-51. PubMed ID: 1619502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.